Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2026-01-04 @ 8:35 PM
Study NCT ID:
NCT05379803
Status:
RECRUITING
Last Update Posted:
2024-09-19
First Post:
2022-05-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Sponsor:
Hunan Province Tumor Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-13
First Submit QC Date:
None
Study First Post Date:
2022-05-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-17
Last Update Post Date:
2024-09-19
Last Update Post Date Type:
ACTUAL